PARIS, FRANCE: Onxeo S.A., a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, announced the formation of a new Scientific Advisory Committee of leading scientific and clinical experts in the fields of DDR, resistance to treatment and more globally, drug development in oncology. The Committee…